RS63266B1 - Fuzionisani benzazepini za lečenje tourette-ovog sindroma - Google Patents

Fuzionisani benzazepini za lečenje tourette-ovog sindroma

Info

Publication number
RS63266B1
RS63266B1 RS20220519A RSP20220519A RS63266B1 RS 63266 B1 RS63266 B1 RS 63266B1 RS 20220519 A RS20220519 A RS 20220519A RS P20220519 A RSP20220519 A RS P20220519A RS 63266 B1 RS63266 B1 RS 63266B1
Authority
RS
Serbia
Prior art keywords
tourette
syndrome
treatment
fused benzazepines
benzazepines
Prior art date
Application number
RS20220519A
Other languages
English (en)
Inventor
Richard E Chipkin
Rudolf Kwan
Original Assignee
Emalex Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emalex Biosciences Inc filed Critical Emalex Biosciences Inc
Publication of RS63266B1 publication Critical patent/RS63266B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
RS20220519A 2012-07-12 2013-07-12 Fuzionisani benzazepini za lečenje tourette-ovog sindroma RS63266B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261671044P 2012-07-12 2012-07-12
EP13815988.4A EP2872145B8 (en) 2012-07-12 2013-07-12 Fused benzazepines for treatment of tourette's syndrome
PCT/US2013/050337 WO2014012034A1 (en) 2012-07-12 2013-07-12 Fused benzazepines for treatment of tourette's syndrome

Publications (1)

Publication Number Publication Date
RS63266B1 true RS63266B1 (sr) 2022-06-30

Family

ID=49916578

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220519A RS63266B1 (sr) 2012-07-12 2013-07-12 Fuzionisani benzazepini za lečenje tourette-ovog sindroma

Country Status (19)

Country Link
US (2) US11298361B2 (sr)
EP (2) EP3919060A1 (sr)
JP (1) JP6181754B2 (sr)
KR (1) KR20150029713A (sr)
CN (1) CN104540510A (sr)
AU (1) AU2013289922B2 (sr)
CA (1) CA2879020C (sr)
DK (1) DK2872145T3 (sr)
ES (1) ES2914043T3 (sr)
HK (1) HK1209336A1 (sr)
HR (1) HRP20220701T1 (sr)
HU (1) HUE058696T2 (sr)
IL (4) IL292725A (sr)
LT (1) LT2872145T (sr)
PL (1) PL2872145T3 (sr)
PT (1) PT2872145T (sr)
RS (1) RS63266B1 (sr)
SI (1) SI2872145T1 (sr)
WO (1) WO2014012034A1 (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2927915C (en) 2013-10-18 2021-10-26 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of stuttering
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477378A (en) 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4973586A (en) 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
US5302716A (en) 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
BE1005064A4 (nl) 1991-07-03 1993-04-06 Asm Fico Tooling Buiginrichting.
GB9127306D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
AU1945495A (en) 1994-03-16 1995-10-03 Novo Nordisk A/S Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
IL135659A0 (en) 1997-10-28 2001-05-20 Schering Corp Method of reducing craving in mammals
HUP0101057A3 (en) * 1998-03-02 2001-09-28 Schering Corp Use of d1/d5 antagonists for preparing pharmaceutical compositions for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
WO2003039468A2 (en) * 2001-11-06 2003-05-15 Haracz John L Antimnemonic therapy for hypermemory syndromes
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2012033874A1 (en) * 2010-09-10 2012-03-15 Chipkin Richard E Method of treating compulsive self-injurious behaviors
CA2927915C (en) 2013-10-18 2021-10-26 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of stuttering

Also Published As

Publication number Publication date
US11298361B2 (en) 2022-04-12
CN104540510A (zh) 2015-04-22
DK2872145T3 (da) 2022-06-13
PL2872145T3 (pl) 2022-06-20
SI2872145T1 (sl) 2022-07-29
HK1209336A1 (en) 2016-04-01
ES2914043T3 (es) 2022-06-07
IL236403A0 (en) 2015-02-26
US20150164911A1 (en) 2015-06-18
JP2015522082A (ja) 2015-08-03
LT2872145T (lt) 2022-06-27
US20210275540A1 (en) 2021-09-09
CA2879020C (en) 2021-02-09
EP3919060A1 (en) 2021-12-08
WO2014012034A1 (en) 2014-01-16
AU2013289922A1 (en) 2015-01-29
IL292725A (en) 2022-07-01
HRP20220701T1 (hr) 2022-07-08
EP2872145A4 (en) 2015-12-02
EP2872145B8 (en) 2022-04-13
IL284615A (en) 2021-08-31
IL300144A (en) 2023-03-01
HUE058696T2 (hu) 2022-09-28
JP6181754B2 (ja) 2017-08-16
EP2872145A1 (en) 2015-05-20
AU2013289922B2 (en) 2016-12-15
KR20150029713A (ko) 2015-03-18
PT2872145T (pt) 2022-05-26
CA2879020A1 (en) 2014-01-16
EP2872145B1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
HRP20200245T1 (hr) Postupci za pripravu (s)-1-(3-etoksi-4metoksifenil)-2-metansulfoniletilamina
HK1211589A1 (en) Compounds for the treatment of paramoxyvirus viral infections
ZA201403795B (en) Formulations for the treatment of diabetes
HK1197400A1 (zh) 治療 的化合物
IL284615A (en) Benzazepines are combined for the treatment of Tourette syndrome
SG11201504201RA (en) Purification of x-ray contrast agents
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
FI3473276T3 (fi) Tekniikoita paiseiden hoitoon
HK1196953A1 (zh) 用於治療糖尿病的製劑
GB201215527D0 (en) Compounds for the treatment of muscular dystrophy